Olema Pharmaceuticals
OLMA
7.94
+0.02
+0.25%
Olema Pharmaceuticals
US · OLMA
#3521 by market cap
Listed 2020
7.94
+0.02
+0.25%
Live - 5344 symbols - heartbeat 288s ago
· 2026-10-08 07:38
Pre-market
8.10
+2.02%
After-hours
7.84
-1.32%
- Market cap
- 694.73M
- P/E (TTM)i
- -3.75
- P/Bi
- 1.61
- EPSi
- -1.87
- Div yieldi
- 0.00%
- 52W posi
- 4%
Reader sentiment
Are you bullish or bearish on OLMA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 2.8 percentage points.
Institutional ownership
- Held by institutions
- 118.36% -2.79pp
- Institutions
- 224 -2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund59.26%
Hedge Fund34.40%
VC/PE Fund17.68%
Public Company4.74%
Individual/Insider2.68%
Family Office/Trust1.15%
Private Company0.59%
Government Pension Fund0.36%
Insurance Company0.17%
Top holders as of 2026-06-30
FMR
13.88% · 12.14M sh
Paradigm Biocapital Advisors LP
9.91% · 8.67M sh
Janus Henderson Group plc
8.11% · 7.09M sh
Bain Capital Life Sciences Investors, LLC
8.10% · 7.09M sh
BlackRock
7.67% · 6.71M sh
BVF Partners L.P.
6.05% · 5.30M sh
Artal Group S.A.
5.55% · 4.86M sh
State Street Global Advisors
4.93% · 4.32M sh
Vanguard Capital Management, LLC
4.29% · 3.76M sh
Logos Global Management, L.P.
3.67% · 3.21M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 23 buys · 25 sells
| Name | Role | Stake |
|---|---|---|
| Cyrus Harmon | Director | 0.94% |
| David Myles | Chief Discovery & Non-Clinical Development Officer | 0.80% |
| Andrew Rappaport | Independent Director | 0.44% |
| Sean Bohen | Chief Executive Officer | 0.27% |
| Cynthia Butitta | Independent Director | 0.10% |
| Sasha Austin | VP of Finance & Controller | 0.02% |
| Naseem Zojwalla | Chief Medical Officer | 0.01% |
| Ian T. Clark | Independent Chairperson of the Board | -- |
| BVF Partners L.P. | -- | -- |
| Sandra Horning | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-31 | Jason O'Byrne | -- | Other Derivative Acquisition | +650,000 | $10.56 |
| 2026-07-23 | Cyrus Harmon | Director | Open Market Disposition | -25,000 | $11.58–11.71 |
| 2026-07-23 | Cyrus Harmon | Director | Intent to Sell (Form 144) | -12,500 | $11.71 |
| 2026-07-22 | Cyrus Harmon | Director | Intent to Sell (Form 144) | -12,500 | $11.58 |
| 2026-06-17 | Andrew Rappaport | Independent Director | Other Derivative Acquisition | +29,500 | $9.51 |
| 2026-06-17 | Cynthia Butitta | Independent Director | Other Derivative Acquisition | +29,500 | $9.51 |
| 2026-06-17 | Ian T. Clark | Independent Chairperson of the Board | Other Derivative Acquisition | +29,500 | $9.51 |
| 2026-06-17 | BVF Partners L.P. | -- | Other Derivative Acquisition | +29,500 | $9.51 |
| 2026-06-17 | Sandra Horning | Independent Director | Other Derivative Acquisition | +29,500 | $9.51 |
| 2026-06-17 | Scott Garland | Director | Other Derivative Acquisition | +29,500 | $9.51 |
| 2026-06-17 | Graham L. Walmsley | Independent Director | Other Derivative Acquisition | +29,500 | $9.51 |
| 2026-06-17 | Yi Larson | Independent Director | Other Derivative Acquisition | +29,500 | $9.51 |
| 2026-06-17 | Prakash Raman | Independent Director | Other Derivative Acquisition | +29,500 | $9.51 |
| 2026-06-17 | Gorjan Hrustanovic | Independent Director | Other Derivative Acquisition | +29,500 | $9.51 |
| 2026-06-17 | Cyrus Harmon | Director | Other Derivative Acquisition | +29,500 | $9.51 |
| 2026-04-27 | Prakash Raman | Independent Director | Other Derivative Acquisition | +27,061 | $14.59 |
| 2026-03-15 | Shane William Kovacs | Chief Operating & Financial Officer | Intent to Sell (Form 144) | -100,000 | $16.08 |
| 2026-03-15 | Shane William Kovacs | Chief Operating & Financial Officer | Intent to Sell (Form 144) | -4,166 | $16.61 |
| 2026-03-10 | Shane William Kovacs | Chief Operating & Financial Officer | Intent to Sell (Form 144) | -50,000 | $15.94 |
| 2026-03-09 | Shane William Kovacs | Chief Operating & Financial Officer | Intent to Sell (Form 144) | -53,206 | $17.00 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:38:44 · For reference only, not investment advice and not tailored to your situation.